ISSN (print) 1997-6933     ISSN (online) 2500-2139
Vol. 18 No. 2 (2025), CLINICAL TRIALS
Vol. 18 No. 2 (2025)
CLINICAL TRIALS

Personalized Approach to Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients with Respect to Molecular Landscape: A Case Report and Literature Review

Published 01.04.2025
Marat Albertovich Mingalimov
City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182; IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435
https://orcid.org/0000-0002-8491-2140
E.A. Baryakh
City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182; IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435; Russian Medical Academy of Postgraduate Education, 2/1 Barrikadnaya ul., Moscow, Russian Federation, 125993
https://orcid.org/0000-0001-6880-9269
T.N. Tolstykh
City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182; IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435
https://orcid.org/0000-0001-7308-0927
A.V. Misyurin
City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182; IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435
https://orcid.org/0000-0003-1349-2879
L.A. Kesaeva
GenoTekhnologiya, 104 Profsoyuznaya ul., Moscow, Russian Federation, 117485
https://orcid.org/0000-0001-8277-8649
A.S. Mkrtchyan
GenoTekhnologiya, 104 Profsoyuznaya ul., Moscow, Russian Federation, 117485
https://orcid.org/0000-0002-0638-213X
A.M. Kovrigina
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
https://orcid.org/0000-0002-1082-8659
E.N. Misyurina
City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182; IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435
https://orcid.org/0000-0003-2419-4850
M.S. Orlova
IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435
https://orcid.org/0009-0009-6369-5413
T.S. Chudnova
City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182; IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435
https://orcid.org/0000-0002-8012-1640
D.D. Ivanova
City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182
https://orcid.org/0009-0004-3632-9198
O.L. Kochneva
City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182
https://orcid.org/0000-0003-1338-8203
S.S. Andreev
City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182
https://orcid.org/0000-0002-9147-4636
K.V. Yatskov
City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182
https://orcid.org/0000-0003-0125-9068
I.V. Samsonova
City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182
https://orcid.org/0000-0002-1228-1765
M.A. Lysenko
City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182
https://orcid.org/0000-0001-6010-7975
2025-2
PDF_2025-18-2-177-183 (Russian)

Keywords

diffuse large B-cell lymphoma
Sanger sequencing
genetic subtypes
precision immunochemotherapy

How to Cite

Mingalimov M.A., Baryakh E.A., Tolstykh T.N., Misyurin A.V., Kesaeva L.A., Mkrtchyan A.S., Kovrigina A.M., Misyurina E.N., Orlova M.S., Chudnova T.S., Ivanova D.D., Kochneva O.L., Andreev S.S., Yatskov K.V., Samsonova I.V., Lysenko M.A. Personalized Approach to Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients with Respect to Molecular Landscape: A Case Report and Literature Review. Clinical Oncohematology. 2025;(2):177–183. doi:10.21320/2500-2139-2025-18-2-177-183.
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA ГОСТ

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Statistics

Annotation views: 8
PDF_2025-18-2-177-183 (Russian) downloads: 9

Keywords

Abstract

The term “Diffuse Large B-Cell Lymphoma” (DLBCL) covers an extremely heterogeneous range of aggressive hematological tumors of lymphoid origin. The recommended standard first-line treatment R-CHOP is still the leading therapy for newly diagnosed DLBCL. However, the outcomes of the unified approach to chemotherapy disregarding a high clinical and molecular genetic heterogeneity of this variant of non-Hodgkin lymphoma are evaluated as unsatisfactory. This paper is the first in the Russian Federation to report the personal experience with the use of the combination of R-CHOP regimen as basic therapy and chemotherapeutic agent acalabrutinib, one of Bruton tyrosine kinase inhibitors, with respect to Sanger sequencing results.

PDF_2025-18-2-177-183 (Russian)

References

  1. 1. Ngu H, Takiar R, Phillips T, et al. Revising the Treatment Pathways in Lymphoma: New Standards of Care-How Do We Choose? Am Soc Clin Oncol Educ Book. 2022;42:1–14. doi: 10.1200/EDBK_349307.
  2. 2. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11. doi: 10.1038/35000501.
  3. 3. Wright GW, Huang DW, Phelan JD, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020;37(4):551–568.e14. doi: 10.1016/j.ccell.2020.03.015.
  4. 4. Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematology Am Soc Hematol Educ Program. 2016;2016(1):366–78. doi: 10.1182/asheducation-2016.1.366.
  5. 5. Hilton LK, Scott DW, Morin RD. Biological heterogeneity in diffuse large B-cell lymphoma. Semin Hematol. 2023;60(5):267–76. doi: 10.1053/j.seminhematol.2023.11.006.
  6. 6. Danilov AV, Magagnoli M, Matasar MJ. Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment. Oncologist. 2022;27(1):57–66. doi: 10.1093/oncolo/oyab004.
  7. 7. Guo L, Lin P, Xiong H, et al. Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment. Biochim Biophys Acta Rev Cancer. 2018;1869(2):85–96. doi: 10.1016/j.bbcan.2018.01.001.
  8. 8. Wen R, Wang D. MCD-DLBCL arises from germinal center B cells. Blood. 2022;140(10):1058–9. doi: 10.1182/blood.2022017534.
  9. 9. Chen R, Zhou D, Wang L, et al. MYD88L265P and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy. Ther Adv Hematol. 2022;13:20406207211072839. doi: 10.1177/20406207211072839.
  10. 10. Alu A, Lei H, Han X, et al. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. J Hematol Oncol. 2022;15(1):138. doi: 10.1186/s13045-022-01353-w.
  11. 11. Dong R, Yan Y, Zeng X, et al. Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical. Drug Des Devel Ther. 2022;16:3225–39. doi: 10.2147/DDDT.S377697
  12. 12. Seymour JF, Byrd JC, Ghia P, et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023;142(8):687–99. doi: 10.1182/blood.2022018818.
  13. 13. Younes A, Sehn LH, Johnson P, et al. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019;37(15):1285–95. doi: 10.1200/JCO.18.02403.
  14. 14. Wilson WH, Wright GW, Huang DW, et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021;39(12):1643–53.e3. doi: 10.1016/j.ccell.2021.10.006.
  15. 15. Zhang MC, Tian S, Fu D, et al. Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial. Cancer Cell. 2023;41(10):1705–16.e5. doi: 10.1016/j.ccell.2023.09.004.
  16. 16. Yu H, Wang X, Li J, et al. Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma. Mol Ther Oncolytics. 2021;21:158–70. doi: 10.1016/j.omto.2021.03.015.
  17. 17. Deng T, Zhang S, Xiao M, et al. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88mut/CD79Bmut diffuse large B-cell lymphoma. Cancer Med. 2024;13(4):e7005. doi: 10.1002/cam4.7005.
  18. 18. Xu P-P, Liu T, Li Z, et al. Efficacy and safety of orelabrutinib in diffuse large B-cell lymphoma: a real-world analysis. J Clin Oncol. 2022;40(16_suppl):e19556. doi: 10.1200/JCO.2022.40.16_suppl.e19556.
  19. 19. Xu P, Fan N, Tian Y, et al. A phase III, randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of orelabrutinib plus R-CHOP versus placebo plus R-CHOP in treatment-naive patients with MCD subtype diffuse large B-cell lymphoma. Blood. 2022;140(Suppl 1):12110. doi: 10.1182/blood-2022-158865.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2025 Clinical Oncohematology